Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KFCNT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-DR5 antibody-curcumin conjugate
|
|||||
| Synonyms |
Anti-DR5 curcumin ADC; DCC
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Hepatic fibrosis/cirrhosis [ICD11:DB93]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-DR5 mAb
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)
|
Antigen Info | ||||
| Payload Name |
Curcumin
|
Payload Info | ||||
| Therapeutic Target |
Arylamine N-acetyltransferase 2 (NAT2)
|
Target Info | ||||
| Linker Name |
Mc-PEG-WDP
|
Linker Info | ||||
| Conjugate Type |
DCC was prepared via a coupling reaction between the maleimide moiety of Mal-PEG-curcumin and the thiol group of the anti-DR5 antibody.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.